Browsing by Author Hassanein, T

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 8 of 8
TitleAuthor(s)Issue DateViews
 
An integrated analysis of phase 2,3 SOF and LDV/SOF trials for the treatment of GT6 HCV Infection
Proceeding/Conference:Hepatology International
Lai, CLChuang, WLHassanein, TKowdley, KVLawitz, EGao, BMo, HMHyland, RYang, JCDe-Oertel, SNatha, MBrainard, DKnox, SJMcHutchison, JGChan, HLYGane, EJ
2016
27
 
Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection
Proceeding/Conference:Journal of Hepatology
Fung, SSulkowski, MLalezari, JSchiff, ERDieterich, DHassanein, TKwo, PElkhashab, MNahass, RAyoub, WHan, SHBonacini, MAlves, KZayed, HHuang, QColonno, RKnox, SRamji, ABennett, MGane, ERavendhran, NPark, JJacobson, IBae, HChan, SHann, HWMa, XNguyen, TYuen, RMF
2020
1
 
Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study
Proceeding/Conference:Journal of Hepatology
Yuen, RMFAgarwal, KMa, XNguyen, TSchiff, ERHann, HWDieterich, DNahass, RPark, JChan, SHan, SHGane, EBennett, MAlves, KZayed, HHuang, QColonno, RKnox, SStamm, LBonacini, MJacobson, IAyoub, WWeilert, FRavendhran, NRamji, AKwo, PElkhashab, MHassanein, TBae, HLalezari, JFung, SSulkowski, M
2020
 
Antiviral activity, pharmacokinetics and safety of the second-generation hepatitis B core inhibitor ABI-H2158 in Phase 1b study of patients with HBeAg-positive chronic hepatitis B infection
Proceeding/Conference:Journal of Hepatology
Agarwal, KNiu, JDing, YGane, ENguyen, TAlves, KEvanchick, MZayed, HHuang, QKnox, SStamm, LColonno, RHassanein, TKim, DJLim, YSYuen, RMF
2020
1
 
Continued therapy with ABI-H0731+NRTI results in sequential reduction/loss of HBV DNA, HBV RNA, HBeAg, HBcrAg and HBsAg in HBeAg positive patients
Proceeding/Conference:Hepatology
Sulkowski, MSAgarwal, KFung, SKYuen, RMFMa, XLLalezari, JPNguyen, TTBae, HSSchiff, ERHassanein, THann, HWLElkhashab, MDieterich, DTKwo, PYNahass, RRamji, APark, JSRavendhran, NChan, SWeilert, FHan, SHBAyoub, WSGane, EJJacobson, IMBennett, MBonacini, MZayed, HAlves, KHuey, VHuang, QRuby, EQiang, DMKnox, SColonno, R
2019
10
 
Integrated analysis of controlled clinical trials evaluating efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C genotype 6 (HCV GT 6)
Proceeding/Conference:Journal of Hepatology
Nguyen, MHChuang, WLHassanein, TKowdley, KLai, CLChan, HLYFeld, JJLetterio, CHahambis, TALlewellyn, JDe-Oertel, SBrainard, DMLawitz, EJGane, EJ
2017
8
 
Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients
Proceeding/Conference:Journal of Hepatology
Ma, XLLalezari, JNguyuen, TBae, HoSchiff, ERFung, SYuen, RMFHassanein, THann, HWElkhashab, MDieterich, DSulkowski, MKwo, PNahass, RAgarwal, KRamji, APark, JRavendhran, NChan, SWeilert, FHan, SHAyoub, WGane, EJacobson, IBennett, MHuang, QYan, RHuey, VRuby, ELiaw, SColonno, RLopatin, U
2019
2
 
The second-generation hepatitis B virus (HBV) core inhibitor (CI) ABI-H2158 is associated with potent antiviral activity in a 14-day monotherapy study in HBeAg-positive patients with chronic hepatitis B (CHB)
Proceeding/Conference:Hepatology
Yuen, RMFAgarwal, KGane, EJNguyen, TTHassanein, TKim, DJAlves, KZayed, HQiang, DMRuby, EEvanchik, MHuang, QKnox, SColonno, Ron behalf of ABI-H2158 Study Team
2019
6
Showing results 1 to 8 of 8